Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 11.91% is 27% below its 5-year average of 16.25%, around the middle of its 5-year range (2.41%–24.79%).
15.76% below its 12-month average of 14.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 13.65%.
EBITDA MARGIN
11.91%
EBITDA MARGIN AVG TTM
14.14%
EBITDA MARGIN AVG 3Y
14.73%
EBITDA MARGIN AVG 5Y
16.25%
EBITDA MARGIN AVG 10Y
15.26%
EBITDA MARGIN AVG 15Y
15.28%
EBITDA MARGIN AVG 20Y
15.69%
CURRENT VS TTM AVG
-15.76%
CURRENT VS 3Y AVG
-19.14%
CURRENT VS 5Y AVG
-26.69%
CURRENT VS 10Y AVG
-21.95%
CURRENT VS 15Y AVG
-22.08%
CURRENT VS 20Y AVG
-24.09%
Market Cap
$5.52B
EBITDA Margin
1.58%
TTM Avg
-0.29%
3Y Avg
0.97%
5Y Avg
0.97%
Market Cap
$5.61B
EBITDA Margin
-4686.36%
TTM Avg
-7375.40%
3Y Avg
-15092.23%
5Y Avg
-12098.10%
Market Cap
$5.32B
EBITDA Margin
51.73%
TTM Avg
11.80%
3Y Avg
-10.91%
5Y Avg
-33.87%
Market Cap
$5.79B
EBITDA Margin
-139.44%
TTM Avg
-176.89%
3Y Avg
-12100.88%
5Y Avg
-12100.88%
Market Cap
$5.21B
EBITDA Margin
-15636.44%
TTM Avg
-8457.23%
3Y Avg
-41454.98%
5Y Avg
-35632.55%
Market Cap
$5.21B
EBITDA Margin
-0.42%
TTM Avg
-60.31%
3Y Avg
-158.65%
5Y Avg
-142.10%
Market Cap
$5.20B
EBITDA Margin
45.70%
TTM Avg
43.81%
3Y Avg
42.07%
5Y Avg
42.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RadNet, Inc. (RDNT) | $5.53B | 11.91% | 14.14% | 14.73% | 16.25% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 1.58% | -0.29% | 0.97% | 0.97% |
| CG Oncology Inc. (CGON)vs › | $5.61B | -4686.36% | -7375.40% | -15092.23% | -12098.10% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 51.73% | 11.80% | -10.91% | -33.87% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | -139.44% | -176.89% | -12100.88% | -12100.88% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | -15636.44% | -8457.23% | -41454.98% | -35632.55% |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.21B | -0.42% | -60.31% | -158.65% | -142.10% |
| Sotera Health Company (SHC)vs › | $5.20B | 45.70% | 43.81% | 42.07% | 42.46% |
| Doximity, Inc. (DOCS)vs › | $5.20B | 35.56% | 38.69% | 36.58% | 34.55% |
Gross Margin
9.7%
EBITDA Margin
11.9%
Operating Margin
4.0%
Net Margin
-0.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 13.65% |
| 2026-03-31 | 4.96% |
| 2025-12-31 | 24.79% |
| 2025-09-30 | 13.86% |
| 2025-06-30 | 13.42% |
| 2025-03-31 | 2.41% |
| 2024-12-31 | 12.69% |
| 2024-09-30 | 14.94% |
| 2024-06-30 | 15.08% |
| 2024-03-31 | 10.12% |
| 2023-12-31 | 16.79% |
| 2023-09-30 | 18.77% |
| 2023-06-30 | 17.96% |
| 2023-03-31 | 13.75% |
| 2022-12-31 | 18.12% |
| 2022-09-30 | 15.33% |
| 2022-06-30 | 18.53% |
| 2022-03-31 | 12.35% |
| 2021-12-31 | 14.46% |
| 2021-09-30 | 22.91% |
| 2021-06-30 | 21.16% |
| 2021-03-31 | 18.45% |
| 2020-12-31 | 19.58% |
| 2020-09-30 | 21.01% |
| 2020-06-30 | 20.13% |
| 2020-03-31 | 10.80% |
| 2019-12-31 | 20.30% |
| 2019-09-30 | 18.57% |
| 2019-06-30 | 20.41% |
| 2019-03-31 | 15.79% |
| 2018-12-31 | 7.36% |
| 2018-09-30 | 14.01% |
| 2018-06-30 | 13.89% |
| 2018-03-31 | 7.33% |
| 2017-12-31 | 14.76% |
| 2017-09-30 | 12.25% |
| 2017-06-30 | 13.38% |
| 2017-03-31 | 10.22% |
| 2016-12-31 | 14.24% |
| 2016-09-30 | 13.25% |
| 2016-06-30 | 10.93% |
| 2016-03-31 | 8.96% |
| 2015-12-31 | 12.62% |
| 2015-09-30 | 15.28% |
| 2015-06-30 | 13.87% |
| 2015-03-31 | 6.81% |
| 2014-12-31 | 15.60% |
| 2014-09-30 | 16.11% |
| 2014-06-30 | 17.22% |
| 2014-03-31 | 13.69% |
| 2013-12-31 | 16.01% |
| 2013-09-30 | 13.33% |
| 2013-06-30 | 15.59% |
| 2013-03-31 | 13.35% |
| 2012-12-31 | 13.34% |
| 2012-09-30 | 16.96% |
| 2012-06-30 | 17.15% |
| 2012-03-31 | 16.14% |
| 2011-12-31 | 19.41% |
| 2011-09-30 | 16.25% |
| 2011-06-30 | 18.71% |
| 2011-03-31 | 15.10% |
| 2010-12-31 | 18.32% |
| 2010-09-30 | 17.41% |
| 2010-06-30 | 17.12% |
| 2010-03-31 | 14.19% |
| 2009-12-31 | 13.35% |
| 2009-09-30 | 22.22% |
| 2009-06-30 | 17.11% |
| 2009-03-31 | 17.95% |
| 2008-12-31 | 14.91% |
| 2008-09-30 | 18.30% |
| 2008-06-30 | 17.95% |
| 2008-03-31 | 17.46% |
| 2007-12-31 | 7.81% |
| 2007-09-30 | 19.70% |
| 2007-06-30 | 19.41% |
| 2007-03-31 | 15.43% |
| 2006-10-31 | 18.46% |
| 2006-07-31 | 19.85% |
| 2006-04-30 | 22.19% |
| 2006-01-31 | 20.81% |
| 2005-10-31 | 21.79% |
| 2005-07-31 | 23.33% |
| 2005-04-30 | 21.23% |
| 2005-01-31 | 18.58% |
| 2004-10-31 | 21.28% |
| 2004-07-31 | 16.32% |
| 2004-04-30 | 18.90% |
| 2004-01-31 | 21.52% |
| 2003-10-31 | 12.28% |
| 2003-07-31 | 21.37% |
| 2003-04-30 | 29.47% |
| 2003-01-31 | 19.39% |
| 2002-10-31 | 17.45% |
| 2002-07-31 | 10.91% |
